PET/CT Volumetric Parameters as Predictors of the Peritoneal Cancer Index in Advanced Ovarian Cancer Patients
<b>Background:</b> Assessment of the peritoneal cancer burden is crucial for determining the optimal treatment in advanced ovarian cancer (AOC). Effective non-invasive methods to predict tumour load remain limited. This study aimed to assess the applicability of 2-[<sup>18</sup>F]FDG PET/CT volumetric parameters, metabolic tumour volume (MTV), and total lesion glycolysis (TLG) for predicting the surgical peritoneal cancer index (PCI) in AOC before primary treatment. <b>Methods:</b> Patients with high-grade serous or undifferentiated AOC who underwent surgical PCI evaluation and 2-[<sup>18</sup>F]FDG PET/CT between 01/2013 and 12/2018 were included. MTV and TLG were calculated using thresholds of 40% and 50% (MTV40, MTV50, TLG40, and TLG50). Correlations between the peritoneal carcinomatosis MTV (car_MTV) and TLG (car_TLG) were analysed. The capacity of volumetric parameters to estimate PCIs above or below 14 and 20 was assessed for the whole abdominal cavity and in per-quadrant analysis, specifically for upper-abdomen areas 1, 2, and 3 (MTV40_1, 2, 3 and TLG40_1, 2, 3). <b>Results:</b> MTV40, MTV50, TLG40, and TLG50 significantly correlated with the PCI in the final study population (<i>n</i> = 45). MTV40 showed a Pearson coefficient of 0.41 (<i>p</i> = 0.003). MTV3_40 (AUC 0.79) and TLG3_40 (AUC 0.81) presented the highest AUCs for predicting a PCI above or below 14. The volumetric parameters allowed the prediction of a PCI greater or less than 20, with an AUC of 0.77 for MTV40_1 and 0.78 for TLG40_1. <b>Conclusions:</b> 2-[<sup>18</sup>F]FDG PET/CT MTV and TLG correlate significantly with the surgical PCI when assessing peritoneal carcinomatosis or quadrant-specific disease. This approach offers a reliable non-invasive method for evaluating tumour burden in AOC.
Authors
- Josep L. Carrasco (ORCID: https://orcid.org/0000-0003-1184-0753)
- Aureli Torné (ORCID: https://orcid.org/0000-0003-4700-9507)
- Lydia Gaba (ORCID: https://orcid.org/0000-0002-6898-0557)
- Ariel Glickman (ORCID: https://orcid.org/0000-0002-5233-5545)
- Marta del Pino (ORCID: https://orcid.org/0000-0003-2178-2403)
- A. Rodríguez (ORCID: https://orcid.org/0000-0002-4899-6607)
- Inmaculada Romero‐Zayas (ORCID: https://orcid.org/0000-0003-1972-284X)
- Eduardo González‐Bosquet
- Pilar Paredes
- Katherine Quintero (ORCID: https://orcid.org/0000-0002-5642-3905)
- Núria Carreras‐Dieguez (ORCID: https://orcid.org/0000-0002-4809-8102)
- Aida Niñerola‐Baizán (ORCID: https://orcid.org/0000-0002-7306-5775)
- Berta Díaz‐Feijoó (ORCID: https://orcid.org/0000-0002-6451-1817)
- Adela Saco (ORCID: https://orcid.org/0000-0001-9935-9045)
- Pere Fusté (ORCID: https://orcid.org/0000-0002-8129-9897)
- David Fuster (ORCID: https://orcid.org/0000-0003-0906-0627)
- Blanca Gil‐Ibáñez (ORCID: https://orcid.org/0000-0002-0361-8741)
- Laura Buñesch
- Tiermes Marina (ORCID: https://orcid.org/0000-0002-3307-5346)
- Cristina Celada-Castro (ORCID: https://orcid.org/0000-0002-3519-1754)
- Marta Tormo
Institutions
- Instituto de Salud Carlos III (ES)
- Research Institute Hospital 12 de Octubre (ES)
- Departament de Salut (ES)
- Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (ES)
- Hospital Clínic de Barcelona (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Diagnostics
- Published
- 2025-07-19
- DOI
- https://doi.org/10.3390/diagnostics15141818
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00